[144] DexCom, Inc. SEC Filing
Rhea-AI Filing Summary
DexCom (DXCM) Form 144 notice reports a proposed sale of 2,750 common shares through UBS Financial Services on NASDAQ, with an aggregate market value of $220,797.50 and approximately 392,155,265 shares outstanding. The shares were acquired as vested RSUs on 05/19/2022 and payment was recorded the same day. The filer notes an approximate sale date of 08/15/2025. The filing also discloses two prior sales by the same account: 2,750 shares on 06/16/2025 for $228,604.75 and 2,750 shares on 07/15/2025 for $234,216.67. The notice includes standard Rule 144 representations but contains no entered dates or signature data in the remarks section.
Positive
- None.
Negative
- None.
Insights
TL;DR: Insider plans to sell 2,750 vested RSU shares via UBS; prior recent sales of identical amounts were disclosed.
The filing documents a routine Rule 144 sale of 2,750 common shares through UBS Financial Services with an indicated sale date of 08/15/2025. Acquisition details show these shares were vested RSUs acquired and paid for on 05/19/2022. The filer also reported two recent sales in June and July 2025, each of 2,750 shares, with gross proceeds disclosed. From a market-impact perspective, the absolute size is small relative to the reported outstanding shares, and the disclosure follows required Rule 144 reporting conventions. The absence of completed entries in the remarks/signature area should be confirmed as an administrative omission.
TL;DR: Filing appears procedurally standard but includes missing entries in the remarks/signature fields that warrant attention.
The Form 144 provides the necessary transaction tables: issuer, broker, class, amount, market value, acquisition source